Apothecary Pharma Recalls Tirzepatide Vials
Compounded tirzepatide injections produced by Apothecary Pharma LLC are subject to a nationwide recall due to a lack of assurance of sterility, USA Today reported. The voluntary recall began on Sept. 24, 2026, after the pharmacy distributed multi-dose vials containing the active ingredient found in brand-name diabetes and weight-loss medications Zepbound and Mounjaro.
The Food and Drug Administration updated the action on Oct. 10, 2026, classifying it as a Class II recall. This designation indicates that using the medication could cause temporary or medically reversible adverse health consequences, though the federal agency noted the risk of serious harm remains small.
FDA Warning Letters and Inspection History
Federal regulators previously warned Apothecary Pharma prior to the recall and issued a warning letter in December 2025. The document cited several violations, including serious deficiencies in production practices for drugs intended to be sterile, which regulators stated put patients at risk. The compounding pharmacy filled prescriptions for custom formulations of GLP-1 medications while operating outside standard commercial drug approval processes.
Compounding pharmacies gained broad production permissions beginning in 2022 when federal regulators allowed them to manufacture custom versions of GLP-1 drugs during national supply shortages. Although tirzepatide and semaglutide subsequently came off the official drug shortage list between late 2024 and early 2025, numerous compounding facilities continued producing and distributing the medications to millions of patients, frequently through telehealth platforms.
Affected Tirzepatide Lot Codes and Expiration Dates
The nationwide recall affects a total of 22 specific multi-dose vials of Apothecary Pharma Tirzepatide Injection formulated at 18mg/mL in 4 mL sterile containers. Customers and medical providers can identify recalled units by checking the lot codes and beyond-use dates printed on the packaging:
- Lot AP-202622, BUD 07-Oct-2026
- Lot AP-202623, BUD 08-Oct-2026
- Lot AP-202624, BUD 19-Oct-2026
- Lot AP-202625, BUD 10/20/2026
- Lot AP-202627, BUD 10/26/2026
- Lot AP-202628, BUD 10/27/2026
- Lot AP-202629, BUD 10/28/2026
- Lot AP-202630, BUD 10/31/2026
- Lot AP-202631, BUD 01-Nov-2026
- Lot AP-202632, BUD 03-Nov-2026
- Lot AP-202633, BUD 07-Nov-2026
- Lot AP-202634, BUD 08-Nov-2026
- Lot AP-202635, BUD 16-Nov-2026
- Lot AP-202636, BUD 17-Nov-2026
- Lot AP-202637, BUD 18-Nov-2026
- Lot AP-202638, BUD 19-Nov-2026
- Lot AP-202639, BUD 20-Nov-2026
- Lot AP-202640, BUD 21-Nov-2026
- Lot AP-202641, BUD 22-Nov-2026
- Lot AP-202642, BUD 24-Nov-2026
- Lot AP-202643, BUD 25-Nov-2026
- Lot AP-202644, BUD 26-Nov-2026
Safety Concerns Surrounding Compounded Peptides
Compounding pharmacies mix raw ingredients to create customized medications, but their final formulations do not undergo federal evaluation for purity, safety, or effectiveness. Past sanitation failures at compounding facilities have led to severe public health emergencies, including a 2012 fungal meningitis outbreak originating from the New England Compounding Center that sickened nearly 800 people and resulted in 64 deaths.
Pharmaceutical manufacturers such as Eli Lilly and Novo Nordisk have filed lawsuits against various compounding entities to restrict the ongoing production of non-approved GLP-1 alternatives. Regulatory oversight remains limited because compounding pharmacies are not subject to routine federal manufacturing inspections in the same manner as major commercial drug makers.
Questions Regarding Recalled Compounded Injections
What should patients do if they possess a recalled vial?
Patients who find they have an affected lot of tirzepatide should stop using the medication immediately. Individuals must contact their prescribing physician or healthcare provider for specific instructions on how to handle or dispose of the recalled product.
How do compounding pharmacies differ from commercial manufacturers?
Commercial manufacturers produce mass-market medications that undergo rigorous FDA approval for safety, purity, and clinical efficacy. Compounding pharmacies create individualized doses or alternative formats from raw ingredients on a custom basis, operating without pre-market federal reviews for each specific batch.
Where can patients verify the standing of a compounding pharmacy?
Patients can check whether a specific compounding pharmacy maintains proper industry standing by visiting the Alliance for Pharmacy Compounding website and consulting with their treating physician.
Worth a look